Literature DB >> 18179367

Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution.

M Beatriz Souza Dias1, Alina Bernardes Habert, Vera Borrasca, Valeska Stempliuk, Aina Ciolli, M Rita E Araújo, Silvia F Costa, Anna S Levin.   

Abstract

OBJECTIVE: To describe the management of patients with long-term central venous catheters (CVCs) during an outbreak of infection due to Pseudomonas putida and Stenotrophomonas maltophilia associated with contaminated heparin catheter-lock solution.
DESIGN: Descriptive study.
SETTING: Private, 250-bed tertiary-care hospital.
METHODS: In March 2003, we identified 2 febrile cancer patients with P. putida bacteremia. Over 2 days, 7 cases of bacteremia were identified; lots of syringes prefilled with heparin catheter-lock solution, supplied by a compounding pharmacy, were recalled and samples were cultured. More cases of bacteremia appeared during the following days, and any patient who had had a catheter lock infused with the suspect solution was asked to provide blood samples for culture, even if the patient was asymptomatic. Isolates that were recovered from culture were typed by pulsed-field gel electrophoresis. Antimicrobial salvage treatment of long-term CVCs was attempted.
RESULTS: A total of 154 patients had had their catheter lock infused with solution from the lots that were suspected of being contaminated. Only 48 of these patients had CVCs. By day 7 of the outbreak, 18 of these patients had become symptomatic. Twenty-six of the remaining 30 asymptomatic patients then also provided blood samples for culture, 10 of whom developed fever shortly after samples were collected. Thirty-two patients were identified who had P. putida bacteremia; 9 also had infection due to S. maltophilia. Samples from 1 of the 3 lots of prefilled syringes in use at the time of the outbreak also grew P. putida on culture. Molecular typing identified 3 different clones of P. putida from patients and heparin catheter-lock solution, and 1 clone of S. maltophilia. A total of 27 patients received antimicrobial therapy regimens, some of which included decontamination of the catheter lock with anti-infective lock solution. Of 27 patients, 19 (70%) retained their long-term CVC during the 6-month follow-up period.
CONCLUSIONS: To our knowledge, this is one of the largest prospective experiences in the management of bloodstream infection associated with long-term CVCs. The infections were caused by gram-negative bacilli and were managed without catheter removal, with a high response rate. We emphasize the risks of using intravenous formulations of medications supplied by compounding pharmacies that produce large quantities of drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18179367     DOI: 10.1086/526440

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey.

Authors:  G Ece; B Erac; M H Limoncu; A Baysak; A T Oz; K C Ceylan
Journal:  West Indian Med J       Date:  2014-04-08       Impact factor: 0.171

2.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.

Authors:  Maristela P Freire; Ligia C Pierrotti; Antonio E Zerati; Luciana Benites; Joaquim Mauricio da Motta-Leal Filho; Karim Y Ibrahim; Pedro H Araujo; Edson Abdala
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Outbreak of adverse reactions associated with contaminated heparin.

Authors:  David B Blossom; Alexander J Kallen; Priti R Patel; Alexis Elward; Luke Robinson; Ganpan Gao; Robert Langer; Kiran M Perkins; Jennifer L Jaeger; Katie M Kurkjian; Marilyn Jones; Sarah F Schillie; Nadine Shehab; Daniel Ketterer; Ganesh Venkataraman; Takashi Kei Kishimoto; Zachary Shriver; Ann W McMahon; K Frank Austen; Steven Kozlowski; Arjun Srinivasan; George Turabelidze; Carolyn V Gould; Matthew J Arduino; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-12-03       Impact factor: 91.245

4.  Incorrect aseptic techniques in medicine preparation and recommendations for safer practices: a systematic review.

Authors:  Eeva Suvikas-Peltonen; Suvi Hakoinen; Ercan Celikkayalar; Raisa Laaksonen; Marja Airaksinen
Journal:  Eur J Hosp Pharm       Date:  2016-10-12

5.  Nosocomial Pseudomonas putida Bacteremia: High Rates of Carbapenem Resistance and Mortality.

Authors:  Seong Eun Kim; Seong-Hwan Park; Hyun Bum Park; Kyung-Hwa Park; Su-Hyun Kim; Sook-In Jung; Jong-Hee Shin; Hee-Chang Jang; Seung Ji Kang
Journal:  Chonnam Med J       Date:  2012-08-24

6.  Diabetic Foot Gangrene Patient with Multi-drug Resistant Pseudomonas Putida Infection in Karawaci District, Indonesia.

Authors:  Nata Pratama Hardjo Lugito; Cucu Nawangsih; Jevany Claudia Moksidy; Andree Kurniawan; Margaret Merlyn Tjiang
Journal:  J Glob Infect Dis       Date:  2015 Jan-Mar

Review 7.  Flushing and Locking of Venous Catheters: Available Evidence and Evidence Deficit.

Authors:  Godelieve Alice Goossens
Journal:  Nurs Res Pract       Date:  2015-05-14

8.  Genomic characterisation of clinical and environmental Pseudomonas putida group strains and determination of their role in the transfer of antimicrobial resistance genes to Pseudomonas aeruginosa.

Authors:  Silke Peter; Philipp Oberhettinger; Leonard Schuele; Ariane Dinkelacker; Wichard Vogel; Daniela Dörfel; Daniela Bezdan; Stephan Ossowski; Matthias Marschal; Jan Liese; Matthias Willmann
Journal:  BMC Genomics       Date:  2017-11-10       Impact factor: 3.969

9.  Infections Caused by Antimicrobial Drug-Resistant Saprophytic Gram-Negative Bacteria in the Environment.

Authors:  Eva Raphael; Lee W Riley
Journal:  Front Med (Lausanne)       Date:  2017-10-30

Review 10.  Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser
Journal:  Front Oncol       Date:  2014-08-25       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.